Tumor growth, metastasis, and migration are dependent upon blood supply to the relevant tissues.28 Active tumor angiogenesis is linked with a short overall survival and poor prognosis in CRC patients.28 In addition to well‐accepted angiogenic factors, such as VEGF and platelet‐derived growth factor, the identification of novel angiogenic mediators specific to CRC is necessary.29 The present study used CD31 immunostaining to show that GNA13 significantly increased the tube formation of HUVECs in vitro and promoted angiogenesis in xenograft tumors. The gene discussed is PECAM1; the disease is neoplasm.